Clinical Insights: July 26, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Ycanth™ (cantharidin) Topical Solution – New Drug Approval – July 21, 2023 – FDA has approved Ycanth™ (cantharidin) for the topical (used on the skin) treatment of molluscum contagiosum…
Clinical Insights: July 19, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Beyfortus™ (nirsevimab-alip) Injection – New Drug Approval – July 17, 2023 – The U.S. Food and Drug Administration approved Beyfortus™ (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV)…
Clinical Insights: July 12, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Leqembi®(lecanemab-irmb) Injection – New Expanded Label – July 12, 2023 – The U.S. Food and Drug Administration converted Leqembi®(lecanemab-irmb), indicated to treat adult…
Clinical Insights: July 5, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Roctavian™ (valoctocogene roxaparvovec-rvox) Suspension for Intravenous Infusion – New Orphan Drug Approval – June 29, 2023 – The U.S. Food and Drug Administration approved Roctavian™, an adeno-associated virus vector-based…
Clinical Insights: June 28, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Litfulo™ (ritlecitinib) – New Drug Approval – June 23, 2023 – Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved Litfulo™ (ritlecitinib), a…
Clinical Insights: June 21, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Columvi® (glofitamab-gxbm) Injection – New Drug Approval – June 15, 2023 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and…
The Latest 340B Insider Podcast Episode is Available!
The process of coordinating specialty care referrals for patients at Federally Qualified Health Centers can be complex. Research shows that several factors, such as poverty, shortages of specialists and referral coordinators, are critical barriers to accessing specialty care for these patients. In our latest 340B Insider Podcast episode, “340B Insights: Breaking Down Access Barriers to…
Clinical Insights: June 14, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Linzess® (linaclotide) Capsules – New Label Expansion – June 12, 2023 – Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today…
Meet us at the 340B Coalition Summer Conference!
Our team members are looking forward to connecting with industry leaders at the upcoming 340B Coalition Summer Conference, July 10-12. We are a proud Pinnacle Partner and can’t wait to connect with fellow 340B leaders! Opportunities to connect with our team during the conference: Schedule an appointment with one of our team members. Schedule a platform demo. Visit…
Clinical Insights: June 7, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Abrysvo™ (respiratory syncytial virus vaccine) Injection – New Drug Approval – May 31, 2023 – Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has…
Clinical Insights: June 1, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Inpefa™ (sotagliflozin) – New Drug Approval – May 26, 2023 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that the U.S. Food and Drug Administration (FDA) has approved Inpefa™ (sotagliflozin),…
Get ready to connect!
Are you attending the 2023 Hospital Pharmacy Summer Session (virtual) conference in June? If so, let’s connect! Schedule an appointment with Heidi Ryan to learn more about our 340B solutions. Schedule a platform demo. Contact us if you need immediate assistance at 877-464-3879. For more than a decade, RxStrategies has provided innovative solutions to assist pharmacy…